What's New

Last Posted: Dec 30, 2024

• Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS).
  Alessandra Trojani, et al. Cancer medicine 2024 0 (24) e70525
• Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.
  Muhammad Hamad Shabir, et al. Applied immunohistochemistry & molecular morphology : AIMM 2024 0 (1) 10-14
• Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
  Cécile Tomowiak, et al. Annals of hematology 2024 0
• Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia.
  Yuting Yan, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 0
• The landscape of rare genetic variants in familial Waldenström macroglobulinemia.
  Alexander Pemov, et al. Blood neoplasia 2024 0 (2)
• Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia.
  Jorge J Castillo, et al. Blood 2023 0
• Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.
  Madeleine R Berendsen, et al. HemaSphere 2023 0 (11) e976
• Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
  David F Moreno, et al. Hematology/oncology clinics of North America 2023 0
• Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
  Francesca Castellani, et al. Neurology(R) neuroimmunology & neuroinflammation 2023 0 (4)
• [Clonotypic analysis of immunoglobulin heavy chain sequences among 44 patients with Waldenström macroglobulinemia].
  Tang Jing, et al. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2023 0 (3) 263-268
• Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study.
  Bhatti Khazra, et al. Journal of hematology 2023 0 (6) 233-239
• Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
  Aldea Mihaela, et al. JCO precision oncology 2023 0 e2200583
• Waldenström macroglobulinemia and non-IgM-type lymphoplasmacytic lymphoma are genetically similar.
  Awata-Shiraiwa Maaya, et al. Acta haematologica 2023 0
• MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
  Abeykoon Jithma P, et al. American journal of hematology 2017 0 (2) 187-194
• Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
  Paludo Jonas, et al. British journal of haematology 2017 0 (1) 98-105
• Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
  Treon Steven P, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 0 (27) 2755-2761
• Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia.
  Zanwar Saurabh, et al. American journal of hematology 2019 0 (3) 274-281
• Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
  Shin Dong Woo, et al. Clinical lymphoma, myeloma & leukemia 2019 0 (8) e496-e505
• Venetoclax in Previously Treated Waldenström Macroglobulinemia.
  Castillo Jorge J, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 0 (1) 63-71
• Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
  Krzisch Daphné, et al. American journal of hematology 2021 0 (12) 1569-1579
• Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
  Abeykoon Jithma P, et al. American journal of hematology 2021 0 (8) 945-953
• Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
  Trojani Alessandra, et al. Cancers 2021 0 (8)
• Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
  Tomowiak Cécile, et al. Blood advances 2021 0 (9) 2438-2446
• Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.
  Alexander J Ryu et al. Blood cancer journal 2023 13(1) 28
• Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
  Gayet Mylene, et al. Cytometry. Part B, Clinical cytometry 2021 0 (1) 62-69
• Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
  Wang Yingjun, et al. Neoplasia (New York, N.Y.) 2021 0 (4) 361-374
• First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia.
  Giuliani F, et al. Annals of hematology 2022 0 (10) 2365-2367
• Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
  Castillo Jorge J, et al. Blood advances 2021 0 (3) 1015-1024
• Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.
  Wang Jun, et al. Blood advances 2022 5
• Clinical application of genomics in Waldenström macroglobulinemia.
  Branagan Andrew R et al. Leukemia & lymphoma 2021 Feb 1-18
• Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.
  McMaster Mary L, et al. Nature communications 2018 0 (1) 4182
• Local Coverage Determination (LCD): Flow Cytometry (L33661)
  The U.S. Centers for Medicare & Medicaid Services
• Toward personalized treatment in Waldenström macroglobulinemia.
  Castillo Jorge J et al. Hematology. American Society of Hematology. Education Program 2017 Dec 2017(1) 365-370
• Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
  Varettoni Marzia, et al. Haematologica 2017 10
• TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.
  Poulain Stéphanie, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 7
• Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.
  Onaindia Arantza et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Jun
• Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
  Cao Xin-Xin, et al. Annals of hematology 2017 3
• Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
  Burnworth Bettina et al. Leukemia research 2016 Dec 5141-48
• Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).
  Kalpadakis Christina, et al. Hematological oncology 2016 10
• Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
  Shin Sang-Yong, et al. Blood research 2016 9 (3) 181-186
• Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
  King Rebecca L, et al. American journal of clinical pathology 2016 6 (6) 843-51
• Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia.
  Roccaro Aldo M, et al. Blood 2016 2
• Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.
  Kuppusamy Hemalatha, et al. PloS one 2014 0 (6) e100691
• MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
  Martinez-Lopez Azahara, et al. The American journal of surgical pathology 2015 5 (5) 644-51
• MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
  Kim Jung-Ah, et al. BioMed research international 2014 0 363540
• Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
  Treon Steven P, et al. Blood 2014 5 (18) 2791-6
• The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.
  Arcaini Luca, et al. Blood 2012 1 (1) 188-91
• Waldenstrom macroglobulinemia
  From NCATS Genetic and Rare Diseases Information Center
• SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.
  Poulain Stéphanie, et al. Leukemia research 2009 9 (9) 1204-7
• The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less.
  Poulain Stéphanie, et al. Haematologica 2008 7 (7) 1109-11

More